Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis. Read more on CMPS stock here.
Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...
Compass Pathways announced that its investigational psilocybin treatment has successfully met its primary endpoint in a Phase ...
The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S.
Compass Pathways’ psilocybin-based drug is edging closer to an approval but faces mixed signals from officials.
Compass Pathways hopes to submit an NDA in Q4 leading up to potential approval.
Stocktwits on MSN
CMPS stock jumps 22% pre-market as Compass sets timeline for new phase 3 depression trial results
Compass announced in January that the FDA had accepted its Investigational New Drug application for COMP360 for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results